【摘要】 <正>滑膜肉瘤（synovial sarcoma,SS）是一种罕见但高度恶性的软组织肉瘤,约占软组织肉瘤的10%^[1],SS并非如其名一样,其起源与滑膜组织无关,因此该名称是一个历史错误。SS特定的起源细胞尚未被证实,但目前的研究认为它可能来源于成肌细胞、神经或原始间充质细胞^[2-4]。现总结如下。一、SS概况SS可发生在任何年龄和任何部位,发病高峰为青壮年^[5],是儿童最常见的非横纹肌源性软组织肿瘤。大多数更多还原

【Abstract】 Synovial sarcoma (SS) is a rare but highly malignant soft tissue sarcoma, which accounts for approximately 10% of all soft tissue sarcomas. At present, its primary management is en bloc resection combined with radiotherapy, chemotherapy, molecular targeted therapy, cellular immunotherapy, etc. The aim of treatment is to improve the survival rate. Due to inoperable resection, recurrence or metastasis, the prognosis of patients with metastases is usually very poor, highlighting the need for more effective therapies to improve outcomes. This article reviews the general situation and treatment progress of synovial sarcoma.更多还原